cannabis
Curaleaf Lawsuit Uncovers Cannabis Benefits Misclaim Drops 27%
Curaleaf Lawsuit Uncovers Cannabis Benefits Misclaim Drops 27% The lawsuits caused a 12% drop in Curaleaf’s share price, yet they also highlight regulatory gaps that could spur a broader overhaul of the cannabis biotech sector. Investors see immediate losses, but policymakers may use the case to tighten labeling standards